Are you up to date on the different myelodysplastic syndromes as defined by the World Health Organization? How about the rate at which some myelodysplastic syndromes turn into leukemia?
Cancer Network Editors
Read compelling analyses of 5-year trends and projected changes in the oncology clinical drug pipeline, selected from the IMS Institute for Healthcare Informatics’ recent “Global Oncology Trend Report.”
Do you know the yearly incidence of each type of leukemia? How about the rate of leukemia in children and adolescents?
Do you know which tests are essential in the workup of newly diagnosed patients with Hodgkin lymphoma? How about the appropriate duration of radiation treatment in these patients? Answer these questions and more.
This slide show highlights some of the top studies and news on colorectal cancer to come out of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.
This slide show highlights some of the top studies and news on lung cancer to come out of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.
Preliminary data from a combination trial of vemurafenib plus PX-866, a nonreversible pan-PI3 kinase inhibitor were presented at the 10th International Congress of the Society for Melanoma Research (SMR) held in Philadelphia.
Final results of a cohort from a phase II monotherapy trial of quizartinib in acute myeloid leukemia patients showed that more than half of patients 60 years of age and older who harbored an internal tandem duplication in the FMS-like tyrosine kinase 3 had a composite complete remission.
In a phase III trial, the oral BRAF inhibitor dabrafenib, improved progression-free survival in previously untreated metastatic melanoma patients.
A study published last month shows that the melanoma drug ipilimumab has activity in melanoma patients whose cancer has spread to the brain. Long-term survival of melanoma patients with brain metastases was comparable to survival of metastatic melanoma patients without brain metastases.